NEW YORK--(

纽约--(

BUSINESS WIRE

商业热线

)--Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced that Chief Executive Officer Marc Viscogliosi will present a corporate overview and update at Biotech Showcase 2025, taking place in San Francisco January 13-15..

)--脊柱生物制药公司（Spine BioPharma，Inc.）是一家致力于退行性椎间盘疾病（DDD）非阿片类非手术治疗的发展阶段公司，今天宣布，首席执行官马克·维斯科利奥西（Marc Viscogliosi）将于1月13日至15日在旧金山举行的2025年生物技术展（Biotech Showcase 2025）上介绍公司概况和最新情况。。

Biotech Showcase 2025 Presentation Details

生物技术展示2025展示详情

Date:

日期：

Tuesday, January 14, 2025

2025年1月14日，星期二

Time:

时间：

3:00 PM PT

3： 下午00点PT

Venue:

地点：

Hilton San Francisco Union Square Hotel, San Francisco, CA (United States)

加利福尼亚州旧金山希尔顿旧金山联合广场酒店（美国）

Room:

房间：

Franciscan-B

方济各会-B

About SB-01 For Injection

关于注射用SB-01

SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine expressed by almost every tissue and cell type, is stored in abundance in the extracellular matrix, and possesses suppressive and stimulatory signaling pathways. In many diseases, there are high concentrations of TGF-Beta that result in a spectrum of negative downstream effects including inflammation, fibrosis, neoinnervation, hyperexcitability of nerves and cell proliferation.

SB-01是一种7个氨基酸的合成肽，可结合并拮抗TGF-β活性。TGF-β是几乎每种组织和细胞类型表达的多效性细胞因子，在细胞外基质中大量储存，并具有抑制和刺激信号通路。在许多疾病中，高浓度的TGF-β会导致一系列负面的下游影响，包括炎症，纤维化，新神经支配，神经过度兴奋和细胞增殖。

SB-01 modulates TGF-Beta concentration, without eliminating it, mitigating the negative downstream effects..

SB-01调节TGF-β浓度，而不消除它，减轻负面的下游影响。。

About Spine BioPharma

关于脊柱生物制药

Spine BioPharma is committed to developing non-opiate, non-surgical treatments that will reduce pain, restore function, and slow or stop pathological disease progression. Spine BioPharma’s lead candidate, SB-01 For Injection, is a first-in-class treatment of DDD, offering potential clinical benefits of pain relief, restoration of function, and prevention of disease progression.

Spine BioPharma致力于开发非阿片类非手术治疗方法，以减轻疼痛，恢复功能，减缓或停止病理性疾病进展。Spine BioPharma的主要候选药物注射用SB-01是DDD的一流治疗药物，具有缓解疼痛，恢复功能和预防疾病进展的潜在临床益处。

To learn more about Spine BioPharma, visit .

要了解更多有关脊柱生物制药的信息，请访问。

www.spinebiopharma.com

www.spinebiopharma.com